Concerns over opioid start stock sell-off

The market value of US biopharma Trevena (Nasdaq: TRVN) is worth just a third of its worth at Monday’s close after a US Food and Drug Administration (FDA) report raised concerns with its opioid injection to treat acute pain.

Trevena’s new drug application (NDA) for oliceridine injection, for the management of moderate-to-severe pain in adult patients for whom an intravenous opioid is warranted, is to be discussed by the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee on Thursday.

The briefing paper presented to the committee has warned the members of the potential risks posed by oliceridine.